Cargando…

Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection

Fecal microbiota transplantation (FMT) is a successful therapeutic strategy for treating recurrent Clostridioides difficile infection. Despite remarkable efficacy, implementation of FMT therapy is limited and the mechanism of action remains poorly understood. Here, we demonstrate a critical role for...

Descripción completa

Detalles Bibliográficos
Autores principales: Littmann, Eric R., Lee, Jung-Jin, Denny, Joshua E., Alam, Zahidul, Maslanka, Jeffrey R., Zarin, Isma, Matsuda, Rina, Carter, Rebecca A., Susac, Bože, Saffern, Miriam S., Fett, Bryton, Mattei, Lisa M., Bittinger, Kyle, Abt, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854624/
https://www.ncbi.nlm.nih.gov/pubmed/33531483
http://dx.doi.org/10.1038/s41467-020-20793-x
Descripción
Sumario:Fecal microbiota transplantation (FMT) is a successful therapeutic strategy for treating recurrent Clostridioides difficile infection. Despite remarkable efficacy, implementation of FMT therapy is limited and the mechanism of action remains poorly understood. Here, we demonstrate a critical role for the immune system in supporting FMT using a murine C. difficile infection system. Following FMT, Rag1 heterozygote mice resolve C. difficile while littermate Rag1(−/−) mice fail to clear the infection. Targeted ablation of adaptive immune cell subsets reveal a necessary role for CD4(+) Foxp3(+) T-regulatory cells, but not B cells or CD8(+) T cells, in FMT-mediated resolution of C. difficile infection. FMT non-responsive mice exhibit exacerbated inflammation, impaired engraftment of the FMT bacterial community and failed restoration of commensal bacteria-derived secondary bile acid metabolites in the large intestine. These data demonstrate that the host’s inflammatory immune status can limit the efficacy of microbiota-based therapeutics to treat C. difficile infection.